Skip to main content
ALK-Abelló logo

ALK-Abelló — Investor Relations & Filings

Ticker · ALK ISIN · DK0061802139 LEI · 529900SGCREUZCZ7P020 CO Manufacturing
Open in API
Filings indexed 1,210 across all filing types
Latest filing 2013-11-01 Report Publication Anno…
Country DK Denmark
Listing CO ALK

About ALK-Abelló

https://www.alk.net

ALK-Abelló is a global, research-driven pharmaceutical company specializing in the prevention, diagnosis, and treatment of allergies. The company is a world leader in allergy immunotherapy (AIT), also known as allergy vaccination, which is a disease-modifying treatment that targets the underlying cause of the allergy rather than just the symptoms. Its portfolio includes a range of allergy treatments and services, with products such as injections, sublingual tablets, and emergency treatments for severe allergic reactions like anaphylaxis. With over a century of experience, ALK-Abelló focuses on developing pharmaceutical products to improve the quality of life for people with allergies globally.

Recent filings

Filing Released Lang Actions
Report Publication Announcement 2013
Report Publication Announcement Classification · 98% confidence The document explicitly states that ALK will release its 'interim report for the nine months ended 30 September 2013' on November 8, 2013. It then details the time and dial-in numbers for a conference call where management will 'review the financial results' and mentions that the 'related presentation will be available shortly before the conference call begins.' Since the document is short (1285 chars) and its primary function is to announce the upcoming release of the interim report and the associated conference call/presentation, it fits the definition of a Report Publication Announcement (RPA). It is not the Interim Report (IR) itself, nor is it the Call Transcript (CT) or Investor Presentation (IP).
2013-11-01 English
Report Publication Announcement 2013
Report Publication Announcement Classification · 99% confidence The document is a short announcement (1071 characters) titled 'Selskabsmeddelelse' (Company Announcement) from ALK. It explicitly states the 'Dato for offentliggørelse af delårsrapport for 9 måneder (Q3) 2013' (Date of publication of the interim report for 9 months (Q3) 2013) and mentions that the associated presentation will be available shortly before the conference call starts. This structure—announcing the future release date and details of an upcoming report (Interim Report/Q3) and associated call—fits the definition of a Report Publication Announcement (RPA), rather than being the report itself (which would be classified as IR).
2013-11-01 English
Regulatory Filings 2013
Regulatory Filings
2013-10-23 English
Regulatory Filings 2013
Regulatory Filings
2013-10-23 Danish
Regulatory Filings 2013
Regulatory Filings Classification · 95% confidence The document is a 'Company release' dated October 8, 2013, announcing a postponement of an FDA Advisory Committee meeting due to a US government shutdown. It discusses regulatory progress (BLA submission) for an investigational drug. This type of announcement, which communicates a specific, non-financial event related to regulatory or legal matters (FDA postponement), fits best under the 'Legal Proceedings Report' (LTR) category if it involves regulatory action, or potentially 'Regulatory Filings' (RNS) as a general announcement. Since it specifically details an update regarding a regulatory review process (FDA BLA discussion postponement), it is a communication about a significant legal/regulatory event involving the company, making LTR a strong candidate. However, given the options, and that it is a general company release about a regulatory event rather than a formal legal filing or a comprehensive ESG/Governance report, the most appropriate general category for non-standard regulatory updates that aren't earnings, dividends, or management changes is often RNS, but LTR covers legal/regulatory proceedings. Given the context of FDA review delays, LTR is slightly more specific than RNS. Since it is not a formal legal proceeding (lawsuit), but a regulatory process update, RNS (General regulatory announcements/fallback) is safer, but let's re-evaluate against LTR. LTR is defined as 'Updates on significant lawsuits, regulatory actions, or legal matters involving the company.' A postponed FDA meeting due to a shutdown qualifies as an update on a significant regulatory matter. I will classify it as LTR due to the focus on the FDA review process delay. The document length is short (3171 chars), but it is the primary content, not an announcement *of* another report, so RPA/RNS based on the 'Menu vs Meal' rule does not apply here.
2013-10-08 English
Regulatory Filings 2013
Regulatory Filings Classification · 100% confidence The document is a press release dated October 8, 2013, announcing that the US FDA has postponed an Allergenic Products Advisory Committee meeting scheduled to discuss a Biologic License Application (BLA) for an investigational drug due to the US government shutdown. This announcement concerns a regulatory process (FDA review) and a specific legal/regulatory event (postponement of a committee meeting). It is not a full financial report (10-K, IR), an earnings release (ER), a dividend notice (DIV), or a management change (MANG). Since it details an update on a significant regulatory/legal matter involving the FDA review process, it best fits the 'Legal Proceedings Report' (LTR) category, as regulatory actions and reviews often fall under this umbrella when other specific categories like ER or AR do not apply. Given the short length and nature as an announcement, it is not the full regulatory filing itself, but an update on the process. LTR covers significant lawsuits and regulatory actions.
2013-10-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.